Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Nov 1;36(41):2767-76.
doi: 10.1093/eurheartj/ehv455. Epub 2015 Sep 1.

Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study

Eloi Marijon  1 , Christophe Leclercq  2 , Kumar Narayanan  3 , Serge Boveda  4 , Didier Klug  5 , Jonathan Lacaze-Gadonneix  6 , Pascal Defaye  7 , Sophie Jacob  8 , Olivier Piot  9 , Jean-Claude Deharo  10 , Marie-Cecile Perier  3 , Genevieve Mulak  11 , Jean-Sylvain Hermida  12 , Paul Milliez  13 , Daniel Gras  14 , Olivier Cesari  15 , Françoise Hidden-Lucet  16 , Frederic Anselme  17 , Philippe Chevalier  18 , Philippe Maury  19 , Nicolas Sadoul  20 , Pierre Bordachar  21 , Serge Cazeau  22 , Michel Chauvin  23 , Jean-Philippe Empana  3 , Xavier Jouven  1 , Jean-Claude Daubert  2 , Jean-Yves Le Heuzey  24 ; CeRtiTuDe Investigators
Collaborators, Affiliations
Comparative Study

Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study

Eloi Marijon et al. Eur Heart J. .

Abstract

Aims: The choice of resynchronization therapy between with (CRT-D) and without (CRT-P) a defibrillator remains a contentious issue. Cause-of-death analysis among CRT-P, compared with CRT-D, patients could help evaluate the extent to which CRT-P patients would have additionally benefited from a defibrillator in a daily clinical practice.

Methods and results: A total of 1705 consecutive patients implanted with a CRT (CRT-P: 535 and CRT-D: 1170) between 2008 and 2010 were enrolled in CeRtiTuDe, a multicentric prospective follow-up cohort study, with specific adjudication for causes of death at 2 years. Patients with CRT-P compared with CRT-D were older (P < 0.0001), less often male (P < 0.0001), more symptomatic (P = 0.0005), with less coronary artery disease (P = 0.003), wider QRS (P = 0.002), more atrial fibrillation (P < 0.0001), and more co-morbidities (P = 0.04). At 2-year follow-up, the annual overall mortality rate was 83.80 [95% confidence interval (CI) 73.41-94.19] per 1000 person-years. The crude mortality rate among CRT-P patients was double compared with CRT-D (relative risk 2.01, 95% CI 1.56-2.58). In a Cox proportional hazards regression analysis, CRT-P remained associated with increased mortality (hazard ratio 1.54, 95% CI 1.07-2.21, P = 0.0209), although other potential confounders may persist. By cause-of-death analysis, 95% of the excess mortality among CRT-P subjects was related to an increase in non-sudden death.

Conclusion: When compared with CRT-D patients, excess mortality in CRT-P recipients was mainly due to non-sudden death. Our findings suggest that CRT-P patients, as currently selected in routine clinical practice, would not potentially benefit with the addition of a defibrillator.

Keywords: Cardiac resynchronization; Cardioverter defibrillator; Competing risk; Heart failure; Sudden death.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall mortality incidence over time according to CRT-P and CRT-D groups. (A) Overall mortality and (B) sudden cardiac death. CRT-D: cardiac resynchronization therapy with defibrillator; CRT-P: cardiac resynchronization therapy without defibrillator.
Figure 2
Figure 2
Forest plots showing unadjusted hazard ratios of CRT-P vs. CRT-D for mortality by different subgroups. CRT-D: cardiac resynchronization therapy with defibrillator; CRT-P: cardiac resynchronization therapy without defibrillator.
See this image and copyright information in PMC

Comment in

References

    1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007. - PubMed
    1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237. - PubMed
    1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization-Heart Failure Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549. - PubMed
    1. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, McKenna W, Fitzgerald M, Deharo JC, Alonso C, Walker S, Braunschweig F, Bailleul C, Daubert JC. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111–118. - PubMed
    1. Gold MR, Linde C, Abraham WT, Gardiwal A, Daubert JC. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm 2011;8:679–684. - PubMed